NOS2 and melanoma: Our present study detected the enhanced inhibition of COX-2 and iNOS expression in melanoma cells after co-treatment with fisetin and melatonin in comparison with single agent treatment, suggesting that inhibition of COX-2 and iNOS signaling at least partially contributed to melatonin potentiated fisetin-mediated cell proliferation inhibition in melanoma cells.